Sugi Predict

Sugi Predict / Compounds / SCHEMBL2860108

SCHEMBL2860108

SCHEMBL2860108

COc1cccc2c(C(F)(F)F)cc(Cl)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.49
▸ ALDH1A1 P00352 6/20 0.46
▸ HPGD P15428 3/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ TNKS O95271 2/20 0.45
▸ TNKS2 Q9H2K2 2/20 0.45
▸ PARP2 Q9UGN5 2/20 0.45
▸ NQO2 P16083 1/20 0.44
▸ GLA P06280 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ HSP90AA1 P07900 1/20 0.42
▸ HSP90AB1 P08238 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ RAD52 P43351 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30122456 1.00 KDM4E (0.49) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL7080293 0.85 KDM4E (0.49) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL2857515 0.84 KDM4E (0.45) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL24715737 0.81 KDM4E (0.49) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL22573248 0.81 NR4A2 (0.42) ALDH1A1LMNAENPP3ENPP1
SCHEMBL30485658 0.81 NR4A2 (0.42) ALDH1A1LMNAENPP3ENPP1
SCHEMBL31690884 0.79 ESR1 (0.39) ALDH1A1LMNAENPP3ENPP1
SCHEMBL1564603 0.79 NQO2 (0.54) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL29420526 0.79 NQO2 (0.54) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL874733 0.79 NQO2 (0.48) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503440-B2 Nitroxoline derivative, preparation method therefor, and use thereof Jiangsu Yahong Meditech Co. (CN) 2025-12-23 — — US disclosed
CN-120035438-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2025-05-23 — — CN disclosed
WO-2024109684-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE 江苏亚虹医药科技股份有限公司 2024-05-30 — — WO disclosed
CN-118059101-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2024-05-24 — — CN disclosed
US-20230295094-A1 NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) 2023-09-21 — — US disclosed
US-20230295094-A1 NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) 2023-09-21 — — US disclosed
US-20230295094-A1 NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) 2023-09-21 — — US disclosed
EP-4194441-A1 NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2023-06-14 — — EP disclosed
EP-4194441-A1 NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2023-06-14 — — EP disclosed
WO-2022028321-A1 NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 江苏亚虹医药科技股份有限公司 2022-02-10 — — WO disclosed
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 — — US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 — — US disclosed
CN-100341862-C Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORP (JP) 2007-10-10 — — CN disclosed
CN-1606549-A Thiazolidine derivative and medical application thereof MITSUBISHI PHARMA CORP (JP) 2005-04-13 — — CN disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 — — US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 KDM4E 1080/4885ALDH1A1 148/4885HPGD 2029/4885
US-12503440-B2 Nitroxoline derivative, preparation method therefor, and use thereof NOS1, NQO1, NOS2 KDM4E 3548/4885ALDH1A1 752/4885HPGD 126/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 KDM4E 1384/4885ALDH1A1 31/4885HPGD 2341/4885
US-20230295094-A1 NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF NOS1, NQO1, NOS2 KDM4E 3548/4885ALDH1A1 752/4885HPGD 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.